MediWound Ltd. (MDWD)
 NASDAQ: MDWD · Real-Time Price · USD
 18.55
 +0.48 (2.66%)
  At close: Oct 30, 2025, 4:00 PM EDT
18.58
 +0.03 (0.16%)
  After-hours: Oct 30, 2025, 4:30 PM EDT
MediWound Revenue
MediWound had revenue of $5.71M in the quarter ending June 30, 2025, with 12.74% growth. This brings the company's revenue in the last twelve months to $19.86M, down -1.41% year-over-year. In the year 2024, MediWound had annual revenue of $20.22M with 8.22% growth.
Revenue (ttm) 
 $19.86M
Revenue Growth 
 -1.41%
P/S Ratio 
 10.03
Revenue / Employee 
 $178,901
Employees 
 111
Market Cap 
237.84M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth | 
|---|---|---|---|
| Dec 31, 2024 | 20.22M | 1.54M | 8.22% | 
| Dec 31, 2023 | 18.69M | -7.81M | -29.48% | 
| Dec 31, 2022 | 26.50M | 2.73M | 11.50% | 
| Dec 31, 2021 | 23.76M | 2.00M | 9.19% | 
| Dec 31, 2020 | 21.76M | -10.03M | -31.54% | 
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue | 
|---|---|
| UnitedHealth Group | 435.16B | 
| Johnson & Johnson | 92.15B | 
| Merck & Co. | 64.24B | 
| Eli Lilly and Company | 59.42B | 
| AbbVie | 58.33B | 
| AstraZeneca | 56.50B | 
| Novartis AG | 56.37B | 
| Novo Nordisk | 49.11B | 
MDWD News
- 4 weeks ago - MediWound Announces $30 Million Registered Direct Offering of Ordinary Shares - GlobeNewsWire
- 5 weeks ago - MediWound Expands Global Reach with Marketing Approval of NexoBrid® in Australia - GlobeNewsWire
- 2 months ago - MediWound's NexoBrid® to be Highlighted in 36 Scientific Presentations at the 21st European Burns Association Congress - GlobeNewsWire
- 2 months ago - MediWound Is A Buy Opportunity On The Dip - Seeking Alpha
- 2 months ago - MediWound to Present at the H.C. Wainwright 27th Annual Global Investment Conference - GlobeNewsWire
- 2 months ago - MediWound Ltd. (MDWD) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - MediWound Reports Second Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 2 months ago - MediWound Announces New EscharEx® Phase II Data Demonstrating Strong Link Between Wound Bed Preparation and Wound Closure in Venous Leg Ulcers - GlobeNewsWire